Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30031260 | 0.80 | ALDH1A1 (0.39) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL10386529 | 0.80 | ALDH1A1 (0.39) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL497771 | 0.78 | ALDH1A1 (0.40) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL8985051 | 0.75 | HMGCR (0.43) | — | |
| SCHEMBL21582004 | 0.75 | ALDH1A1 (0.37) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL22816036 | 0.73 | ALDH1A1 (0.36) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL10561417 | 0.72 | ALDH1A1 (0.39) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL18446 | 0.72 | ALDH1A1 (0.53) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL4132648 | 0.71 | ALDH1A1 (0.37) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL3144067 | 0.71 | ALDH1A1 (0.37) | ALDH1A1LMNAHSD17B10ALOX15MGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6770646-B2 | PYRROLO-, THIENO-, FURANO-AND PYRAZOLO-(3,4-D)-PYRIDAZINONES; USED FOR TREATING REVERSIBLE OBSTRUCTIVE AIRWAYS DISEASE AND EFFECTING IMMUNOSUPPRESSION | ASTRAZENECA AB (SE) | 2004-08-03 | — | — | US | disclosed |
| EP-1036076-B1 | NOVEL COMPOUNDS | ASTRAZENECA UK LTD (GB) | 2002-09-04 | — | — | EP | disclosed |
| US-20020099055-A1 | Novel compounds | ASTRAZENECA AB. | 2002-07-25 | — | — | US | disclosed |
| US-6342601-B1 | TREATING ALLOGRAFT REJECTION, RHEUMATOID ARTHRITIS | ASTRAZENECA AB (SE) | 2002-01-29 | — | — | US | disclosed |
| EP-1036076-A1 | NOVEL COMPOUNDS | AstraZeneca UK Limited (GB) | 2000-09-20 | — | — | EP | disclosed |
| WO-1999029695-A1 | NOVEL COMPOUNDS | ASTRAZENECA UK LIMITED (GB) | 1999-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099055-A1 | Novel compounds | THPO, CYP4B1, CYP3A4 | ALDH1A1 2122/4885LMNA 2760/4885HSD17B10 1585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.